A Phase 1 interventional study of Sotatercept and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn about the safety of 2 different amounts of sotatercept and if healthy Chinese people tolerate them. The study will also measure what happens to sotatercept in a person's body over time (pharmacokinetic or PK study).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of sotatercept at dose level 1.
Biological: Sotatercept
Participants received a single dose of sotatercept at dose level 2.
Biological: Sotatercept
Participants received a single dose of placebo to sotatercept.
Other: Placebo
Single subcutaneous injection
Also known as: MK-7962, ActRIIA-IgG1Fc, ACE-011
Single subcutaneous injection
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 120 days
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to approximately 120 days
Maximum Serum Concentration (Cmax) of Sotatercept
Blood samples will be collected to determine the Cmax of sotatercept.
Time frame: At designated timepoints (up to 120 days)
Time to Maximum Serum Concentration (Tmax) of Sotatercept
Blood samples will be collected to determine the Tmax of sotatercept.
Time frame: Predose and at designated timepoints up to 120 days postdose
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-7962
Blood samples will be collected to determine the AUC0-last of MK-7962.
Time frame: At designated timepoints (up to 120 days)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-7962
Blood samples will be collected to determine the AUC0-inf of MK-7962.
Time frame: At designated timepoints (up to 120 days)
Area Under the Concentration-Time Curve from Time 0 to 28 days (AUC0-28 days) of MK-7962
Blood samples will be collected to determine the AUC0-28 days of MK-7962.
Time frame: At designated timepoints (up to 28 days postdose)
Apparent Terminal Half-life (t1/2) of MK-7962
Blood samples will be collected to determine the t1/2 of MK-7962.
Time frame: At designated timepoints (up to 120 days)
Apparent Clearance (CL/F) of MK-7962
Blood samples will be collected to determine the CL/F of MK-7962.
Time frame: At designated timepoints (up to 120 days)
Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-7962
Blood samples will be collected to determine the Vz/F of MK-7962.
Time frame: At designated timepoints (up to 120 days)
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2023 to primary completion in May 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept